Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients
NCT ID: NCT00394927
Last Updated: 2012-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2007-04-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of epilepsy requiring AED treatment
* Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
* Treatment must be stable for at least 3 months prior to assessment
* Absence of other severe and/or uncontrolled symptomatic chronic illness
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Bureau for Epilepsy
OTHER
UCB Pharma
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sonja Buyle, M.D.
Role: STUDY_DIRECTOR
UCB Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vienna, , Austria
Blansko, , Czechia
České Budějovice, , Czechia
Hradec Králové, , Czechia
Karlovy Vary, , Czechia
Kopřivnice, , Czechia
Kroměříž, , Czechia
Liberec, , Czechia
Litomyšl, , Czechia
Náchod, , Czechia
Nové Město na Moravě, , Czechia
Prague, , Czechia
Teplice, , Czechia
Třebíč, , Czechia
Ústí nad Labem, , Czechia
Zlín, , Czechia
Aschaffenburg, , Germany
Berlin, , Germany
Bielefeld, , Germany
Bochum, , Germany
Cologne, , Germany
Düsseldorf, , Germany
Ellwangen, , Germany
Göttingen, , Germany
Hirschaid, , Germany
Jena, , Germany
Königsbrück, , Germany
Krefeld, , Germany
Leipzig, , Germany
München, , Germany
Neuberg, , Germany
Oelde, , Germany
Albano Laziale (Roma), , Italy
Napoli, , Italy
Bialystok, , Poland
Elblag, , Poland
Gdansk, , Poland
Katowice, , Poland
Kielce, , Poland
Krakow, , Poland
Lublin, , Poland
Poznan, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Botoșani, , Romania
Brasov, , Romania
Bucharest, , Romania
Craiova, , Romania
Galati, , Romania
Iași, , Romania
Lasi, , Romania
Timișoara, , Romania
Sant Boi de Llobregat, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N01228
Identifier Type: -
Identifier Source: org_study_id